58O Real-world overall survival (OS) with durvalumab (D) after chemoradiotherapy (CRT) in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC): Interim analysis from the PACIFIC-R study. (December 2022) - Girard, N.; Christoph, D.C.C.; Garassino, M.C.; McDonald, F.; Mornex, F.; Field, J.K.; Fietkau, R.; Garrido Lopez, P.; Haakensen, V.D.; Siva, S.; van den Heuvel, M.; Bar, J.; et al.